Abivax's recent funding round, which raised $920 million, allows the biotech firm to focus on launching its lead drug, obefazimod, in the U.S. without the need for backing from larger pharmaceutical companies. CEO Marc de Garidel stated that the company is now financially equipped to sustain operations until the end of 2029 and build the necessary infrastructure for the U.S. market.
This funding comes after a tumultuous period for Abivax, marked by investor anxiety over reported cancer cases in a late-stage trial for obefazimod, which initially caused a significant drop in share prices. However, subsequent data indicated that the cancer rates were consistent with expected levels for the patient demographic, helping to stabilize the stock.
De Garidel emphasized the drug's efficacy in treating ulcerative colitis and reiterated its safety profile, noting the heightened cancer risk associated with the disease itself. The company plans to meet with the U.S. Food and Drug Administration later this month to discuss its New Drug Application for obefazimod.
Despite speculation about a potential takeover, which has been fueled by the drug's strong performance in trials, Abivax's soaring share price—up over 1,600% in the past year—could complicate any acquisition discussions.
Analysts suggest that if an acquisition were to occur, it could be valued at around $23 billion, making Abivax an attractive target for larger firms in the immunology and inflammation sectors